127 related articles for article (PubMed ID: 36423971)
1. Prasugrel and Ticagrelor Treatment Among Patients With ACS: Is There a Need for a New Randomized Trial?
Wöhrle J; Seeger J
JACC Cardiovasc Interv; 2022 Nov; 15(22):2281-2283. PubMed ID: 36423971
[No Abstract] [Full Text] [Related]
2. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
Galli M; Benenati S; Franchi F; Rollini F; Capodanno D; Biondi-Zoccai G; Vescovo GM; Cavallari LH; Bikdeli B; Ten Berg J; Mehran R; Gibson CM; Crea F; Pereira NL; Sibbing D; Angiolillo DJ
Eur Heart J; 2022 Mar; 43(10):959-967. PubMed ID: 34918066
[TBL] [Abstract][Full Text] [Related]
3. De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials.
Abdelazeem B; Shehata J; Abbas KS; El-Shahat NA; Baral N; Adhikari G; Khan H; Hassan M
Am J Cardiovasc Drugs; 2022 May; 22(3):287-298. PubMed ID: 34651261
[TBL] [Abstract][Full Text] [Related]
4. Real-World Evidence on Disparities on the Initiation of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome.
Yildirim M; Mueller-Hennessen M; Milles BR; Biener M; Hund H; Frey N; Giannitsis E; Salbach C
J Am Heart Assoc; 2023 Aug; 12(16):e030879. PubMed ID: 37581388
[TBL] [Abstract][Full Text] [Related]
5. Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Trials.
Ray A; Najmi A; Khandelwal G; Jhaj R; Sadasivam B
Cardiovasc Drugs Ther; 2021 Jun; 35(3):561-574. PubMed ID: 32816142
[TBL] [Abstract][Full Text] [Related]
6. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention.
Abraham NS; Yang EH; Noseworthy PA; Inselman J; Yao X; Herrin J; Sangaralingham LR; Ngufor C; Shah ND
Aliment Pharmacol Ther; 2020 Aug; 52(4):646-654. PubMed ID: 32657466
[TBL] [Abstract][Full Text] [Related]
7. Head to head comparison of Prasugrel versus Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials.
Bundhun PK; Shi JX; Huang F
BMC Pharmacol Toxicol; 2017 Dec; 18(1):80. PubMed ID: 29233189
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of oral P2Y
Farmakis IT; Zafeiropoulos S; Doundoulakis I; Pagiantza A; Karagiannidis E; Moysidis DV; Stalikas N; Kassimis G; Michalis LK; Karvounis H; Giannakoulas G
Open Heart; 2022 Apr; 9(1):. PubMed ID: 35428703
[TBL] [Abstract][Full Text] [Related]
9. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
Gimbel M; Qaderdan K; Willemsen L; Hermanides R; Bergmeijer T; de Vrey E; Heestermans T; Tjon Joe Gin M; Waalewijn R; Hofma S; den Hartog F; Jukema W; von Birgelen C; Voskuil M; Kelder J; Deneer V; Ten Berg J
Lancet; 2020 Apr; 395(10233):1374-1381. PubMed ID: 32334703
[TBL] [Abstract][Full Text] [Related]
10. Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes : Results From a Randomized Trial.
Menichelli M; Neumann FJ; Ndrepepa G; Mayer K; Wöhrle J; Bernlochner I; Richardt G; Witzenbichler B; Sibbing D; Gewalt S; Angiolillo DJ; Lahu S; Hamm CW; Hapfelmeier A; Trenk D; Laugwitz KL; Schunkert H; Schüpke S; Kastrati A
Ann Intern Med; 2020 Sep; 173(6):436-444. PubMed ID: 32687741
[TBL] [Abstract][Full Text] [Related]
11. [The ISAR-REACT 5 trial: is there a winner between prasugrel and ticagrelor in acute coronary syndromes?].
Ferlini M; Galvani M; Visconti LO
G Ital Cardiol (Rome); 2020 Mar; 21(3):171-174. PubMed ID: 32100728
[No Abstract] [Full Text] [Related]
12. Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database.
Blin P; Dureau-Pournin C; Benichou J; Bonello L; Dallongeville J; Danchin N; Falissard B; Thomas-Delecourt F; Jové J; Lassalle R; Droz C; Moore N
Atherosclerosis; 2019 Feb; 281():98-106. PubMed ID: 30658197
[TBL] [Abstract][Full Text] [Related]
13. In ACS, ticagrelor and prasugrel each reduce some ischemic events but increase major bleeding vs. clopidogrel.
Nanna MG; Granger CB
Ann Intern Med; 2020 Oct; 173(8):JC44. PubMed ID: 33075264
[TBL] [Abstract][Full Text] [Related]
14. Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial.
Behnes M; Lahu S; Ndrepepa G; Menichelli M; Mayer K; Wöhrle J; Bernlochner I; Gewalt S; Witzenbichler B; Hochholzer W; Sibbing D; Cassese S; Angiolillo DJ; Hemetsberger R; Valina C; Müller A; Kufner S; Hamm CW; Xhepa E; Hapfelmeier A; Sager HB; Joner M; Fusaro M; Richardt G; Laugwitz KL; Neumann FJ; Schunkert H; Schüpke S; Kastrati A; Akin I
Clin Res Cardiol; 2023 Apr; 112(4):518-528. PubMed ID: 35789430
[TBL] [Abstract][Full Text] [Related]
15. A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study.
Jin C; Kim MH; Bang J; Serebruany V
Cardiology; 2017; 138(4):201-206. PubMed ID: 28810251
[TBL] [Abstract][Full Text] [Related]
16. Access Route and Clinical Outcomes After Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome Undergoing Invasive Treatment Strategy.
Hemetsberger R; Richardt G; Lahu S; Valina C; Menichelli M; Abdelghani M; Wöhrle J; Toelg R; Witzenbichler B; Mankerious N; Liebetrau C; Bernlochner I; Hamm CW; Allali A; Joner M; Fusaro M; Xhepa E; Hapfelmeier A; Kufner S; Sager HB; Schüpke S; Laugwitz KL; Schunkert H; Neumann FJ; Kastrati A; Cassese S
Cardiovasc Revasc Med; 2022 Aug; 41():122-128. PubMed ID: 35045943
[TBL] [Abstract][Full Text] [Related]
17. Ticagrelor versus prasugrel in acute coronary syndrome: sex-specific analysis from the RENAMI Registry.
Al Raisi S; Protty M; Raposeiras-Roubín S; D'Ascenzo F; Abu-Assi E; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Quadri G; Rognoni A; Boccuzzi G; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Flores-Blanco P; Varbella F; Cespón-Fernández M; Gallo D; Morbiducci U; Domínguez-Rodríguez A; Cequier Á; Gaita F; Alexopoulos D; Valgimigli M; Íñiguez-Romo A; Kinnaird T
Minerva Cardiol Angiol; 2021 Aug; 69(4):408-416. PubMed ID: 34137238
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness and safety of antiplatelet drugs in patients with diabetes mellitus and acute coronary syndrome.
Spoendlin J; Gagne JJ; Lewey JJ; Patorno E; Schneeweiss S; Desai RJ
Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1361-1370. PubMed ID: 30379372
[TBL] [Abstract][Full Text] [Related]
19. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome in Relation to Estimated Glomerular Filtration Rate.
Wöhrle J; Seeger J; Lahu S; Mayer K; Bernlochner I; Gewalt S; Menichelli M; Witzenbichler B; Hochholzer W; Sibbing D; Cassese S; Angiolillo DJ; Hemetsberger R; Valina C; Kufner S; Xhepa E; Hapfelmeier A; Sager HB; Joner M; Richardt G; Laugwitz KL; Neumann FJ; Schunkert H; Schüpke S; Kastrati A; Ndrepepa G
JACC Cardiovasc Interv; 2021 Sep; 14(17):1857-1866. PubMed ID: 34446390
[TBL] [Abstract][Full Text] [Related]
20. The effect of a Prasugrel- vs. a Ticagrelor-based strategy on total ischaemic and bleeding events in patients with acute coronary syndromes.
Aytekin A; Coughlan JJ; Ndrepepa G; Cassese S; Lahu S; Kufner S; Mayer K; Xhepa E; Gewalt S; Joner M; Hapfelmeier A; Angiolillo DJ; Menichelli M; Richardt G; Neumann FJ; Schunkert H; Kastrati A
Eur Heart J Cardiovasc Pharmacother; 2023 Apr; 9(3):231-239. PubMed ID: 36434779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
